XML 71 R47.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Organization and Significant Accounting Policies, Fair Value Measurements (Details) - Recurring Basis [Member] - USD ($) $ in Thousands | Dec. 31, 2019 | Dec. 31, 2018
--- | --- | ---
Fair Value Measurements [Abstract] |  |  |  |  |
Cash equivalents | [1] | $ 418,406 |  | $ 146,281 |
Investment in ProQR Therapeutics N.V. | [2] | 4,506 |  | 1,349 |
Total |  | 2,258,985 |  | 2,017,298 |
Corporate Debt Securities [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 1,102,568 | [3] | 1,252,960 | [4]
Corporate Debt Securities [Member] | Cash and Cash Equivalents [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 19,000 |  | 50,200 |
Debt Securities issued by U.S. Government Agencies [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 329,404 | [5] | 276,612 | [6]
Debt Securities issued by U.S. Government Agencies [Member] | Cash and Cash Equivalents [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 800 |  |  |
Debt Securities issued by the U.S. Treasury [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 363,694 | [6] | 260,154 | [7]
Debt Securities issued by the U.S. Treasury [Member] | Cash and Cash Equivalents [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  |  |  | 14,200 |
Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities | [6] | 40,407 |  | 79,942 |
Quoted Prices in Active Markets (Level 1) [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Cash equivalents |  | 418,406 |  | 146,281 |
Investment in ProQR Therapeutics N.V. |  | 0 |  | 0 |
Total |  | 782,100 |  | 406,435 |
Quoted Prices in Active Markets (Level 1) [Member] | Corporate Debt Securities [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 0 |  | 0 |
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities issued by U.S. Government Agencies [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 0 |  | 0 |
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities issued by the U.S. Treasury [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 363,694 |  | 260,154 |
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 0 |  | 0 |
Significant Other Observable Inputs (Level 2) [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Cash equivalents |  | 0 |  | 0 |
Investment in ProQR Therapeutics N.V. |  | 0 |  | 0 |
Total |  | 1,472,379 |  | 1,609,514 |
Significant Other Observable Inputs (Level 2) [Member] | Corporate Debt Securities [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 1,102,568 |  | 1,252,960 |
Significant Other Observable Inputs (Level 2) [Member] | Debt Securities issued by U.S. Government Agencies [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 329,404 |  | 276,612 |
Significant Other Observable Inputs (Level 2) [Member] | Debt Securities issued by the U.S. Treasury [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 0 |  | 0 |
Significant Other Observable Inputs (Level 2) [Member] | Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 40,407 |  | 79,942 |
Significant Unobservable Inputs (Level 3) [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Cash equivalents |  | 0 |  |  |
Investment in ProQR Therapeutics N.V. |  | 4,506 |  | 1,349 |
Total |  | 4,506 |  | 1,349 |
Significant Unobservable Inputs (Level 3) [Member] | Corporate Debt Securities [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Cash equivalents |  |  |  | 0 |
Available-for-sale securities |  | 0 |  | 0 |
Significant Unobservable Inputs (Level 3) [Member] | Debt Securities issued by U.S. Government Agencies [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 0 |  | 0 |
Significant Unobservable Inputs (Level 3) [Member] | Debt Securities issued by the U.S. Treasury [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | 0 |  | 0 |
Significant Unobservable Inputs (Level 3) [Member] | Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member] |  |  |  |  |
Fair Value Measurements [Abstract] |  |  |  |  |
Available-for-sale securities |  | $ 0 |  | $ 0 |
[1] | Included in cash and cash equivalents on our consolidated balance sheet.
[2] | Included in other current assets on our consolidated balance sheet.
[3] | $19.0 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.
[4] | $50.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.
[5] | $0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.
[6] | Included in short-term investments.
[7] | $14.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading. + References No definition available. + Details
Name: | us-gaap_AvailableForSaleSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + References No definition available. + Details
Name: | us-gaap_CashAndCashEquivalentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740 + Details
Name: | us-gaap_EquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_FairValueNetAssetLiabilityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |